A Prospective, Open label, Randomized, Comparative, Two arm, Multi-centric, Investigator initiated study to evaluate efficacy and safety of Levonadifloxacin with Teicoplanin-Aztreonam combination in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI) including diabetic foot infection

开始日期2022-06-15

申办/合作机构

Wockhardt Ltd.

CTRI/2022/05/042613 / Not yet recruitingN/AIIT

A Prospective, Open label, Randomized, Comparative, Two arm, Multi-centric, Investigator initiated study to evaluate efficacy and safety of Levonadifloxacin with Teicoplanin-Azithromycin combination in hospitalized patients with Community Acquired Bacterial Pneumonia (CABP)

开始日期2022-05-23

申办/合作机构-

100 项与 Levonadifloxacin arginine salt 相关的临床结果

登录后查看更多信息

100 项与 Levonadifloxacin arginine salt 相关的转化医学

登录后查看更多信息

100 项与 Levonadifloxacin arginine salt 相关的专利（医药）

登录后查看更多信息

项与 Levonadifloxacin arginine salt 相关的文献（医药）

2024-10-01·Access microbiology

Bacterial profile of wound site infections and evaluation of risk factors for sepsis among road traffic accident patients from Apex Trauma Centre, Northern India

Article

作者: Singh, Amit Kumar ; Sahu, Chinmoy ; Varghese, Gerlin ; Tejan, Nidhi ; Singh Patel, Sangram ; Singh, Pooja ; Ghar, Malay ; Singh, Aparna ; Jamwal, Ashima

Background. Among the most significant yet often ignored health issues worldwide are trauma and accidental injuries. India accounts for 11% of global deaths in road accidents, the highest in the world, according to the World Bank report. There are limited data about the bacterial contamination of road traffic accident (RTA) wounds and their antibiotic susceptibility patterns.Materials and Methods. This prospective study was conducted in a tertiary care centre in northern India from January 2023 to January 2024. Wound deep swabs or aspirates were collected from RTA patients with traumatic injuries at different time intervals. Gram stain and culture were performed, and positive aerobic culture was subjected to antibiotic susceptibility testing. Organism identification was done using MALDI-TOF MS and routine biochemical tests. Blood samples were also collected to rule out bloodstream infections during follow-up if the patient became febrile or showed symptoms of systemic infection. Sepsis was defined in those patients who had two or more scores in the systemic inflammatory response syndrome criteria with a positive microbiological culture. Risk factors were evaluated for sepsis on the basis of the patient’s vitals, injury characteristics, procalcitonin, Glasgow Coma Scale (GCS) score, need for mechanical ventilation and complete blood count, which were obtained from the patient’s admission file.Results. A total of 189 wound samples were collected, of which 99 (52.38%) samples showed the growth of microorganisms. The aerobic isolates included 69 (69.69%) Gram-negative bacilli, of which the majority were Klebsiella pneumoniae, 28 (28.28%) Gram-positive cocci, of which the majority were Staphylococcus aureus and 2 (2.02%) anaerobic isolates. Among the Gram-negative isolates, none of the isolates were resistant to colistin. All S. aureus isolates were susceptible to vancomycin, teicoplanin and levonadifloxacin. Sepsis developed in 50 (26.45 %) patients. Significant risk factors evaluated for sepsis were a raised procalcitonin level, a low GCS score, a higher injury severity score, the need for mechanical ventilation and a raised quick sequential organ failure assessment score.Conclusion. It is essential to ascertain the profile of microorganisms isolated from RTA wounds in order to reduce antibiotic resistance and deliver efficient treatment.

2024-04-01·Microbial drug resistance (Larchmont, N.Y.)

In Vitro Assessment of Antimicrobial Activity of Novel Fluoroquinolone, Levonadifloxacin (WCK 771) Against Multi-Drug-Resistant Clinical Isolates from Cancer Patients in India

Article

作者: Sarode, Rahul ; Pandey, Himanshu ; Bajpai, Vijeta ; Mishra, Anwita ; Bharti, Sujit ; Sure, Rashmi ; Tiwari, Shashank ; Kapoor, Akhil

Introduction: Rapid increase in antimicrobial-resistance is leading to urgent need for newer broad-spectrum antimicrobials. Therefore, we have evaluated the antimicrobial résistance spectrum of India-discovered novel antibiotics (levonadifloxacin) against clinical isolates recovered from cancer patients. Materials and Methods: The study was conducted in the microbiology department, over a period of 1 year between May 2021 and June 2022 and 374 consecutive and nonduplicate Gram-positive (GPC) and MDR Gram Negative Bacteria (GNB) isolate were analyzed from 3,880 cancer patients in study. The identification and antimicrobial sensitivities of bacterial isolates were performed according to standard laboratory protocols by using automated identification system (VITEK-2-8.01; BioMérieux, Germany). The activity of levonadifloxacin and comparator antibiotics was evaluated using disk diffusion methods as per Clinical and Laboratory Standards Institute 2022 guidelines. Results: The mean age of the patients were 51.6 ± 14.59 years with male: female ratio of 1.2:1. The prevalence of GPC was 167 (44.65%) and MDR-GNB was 207 (55.34%). The most common GPC was Staphylococcus aureus; 97 (58.08%) followed by Enterococcus species 66 (39.52%). In GNB, Escherichia coli; 93 (44.92%) was the most common followed by Klebsiella pneumoniae; 45 (21.73%). Levonadifloxacin susceptibility was present in 98.7% methicillin-resistant S. aureus and 96% methicillin-susceptible S. aureus and 77.1% Enterococcus-species. Additionally, all the fluoroquinolones-resistant S. aureus isolates were susceptible to levonadifloxacin (WCK-771) except one isolate. Also, levonadifloxacin-(WCK-771) exhibits 100% susceptibility fluoroquinolone susceptible GNB, such as E. coli, K. pneumoniae, Pseudomonas species, and Acinetobacter species. Interestingly, all fluoroquinolones-resistant Salmonella species and Stenotrophomonas maltophilla exhibited 100% susceptibility to levonadifloxacin (WCK-771). Conclusion: Levonadifloxacin (WCK-771) possesses potent activity against all the MDR Gram-positive pathogens including the coverage of susceptible Enterobacterales and MDR S. maltophilla and Burkholderia cepacia suggesting its potential utility in the management of polymicrobial infections.

2024-02-28·Cureus

Efficacy and Safety of Oral and IV Levonadifloxacin Therapy in Management of Bacterial Infections: Findings of a Prospective, Observational, Multi-center, Post-marketing Surveillance Study

Article

作者: Dubey, Dilip ; Newale, Sanket ; Zirpe, Kapil ; Mehta, Yatin ; Debnath, Khokan ; Sutar, Anand ; Saseedharan, Sanjith

Background Antimicrobial resistance by bacteria poses a substantial threat to morbidity and mortality worldwide, and treatment of resistant infections is a challenge for the treating clinician. Levonadifloxacin is a novel broad-spectrum agent belonging to the benzoquinolizine subclass of quinolone, which can be used by both oral and intravenous administration for the treatment of infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). Patients and methods This prescription event monitoring study captured data from 1266 patients receiving levonadifloxacin (oral and/or IV) in a real-world setting to assess the safety and efficacy in the treatment of various bacterial infections. The duration of the study was 18 months. Study outcomes were clinical success and microbial success at the end of therapy. Global assessments were done for safety and efficacy at the end of therapy using a 5-point Likert scale (excellent, very good, good, satisfactory, and poor). Results The mean (median) duration of therapy was 7.2 (7.0) days, with a median time to clinical improvement of four days. Oral therapy was administered to 224 patients; 940 received IV, and 102 received IV followed by oral therapy. Patients were prescribed levonadifloxacin for gram-positive infections, skin and soft tissue infections, diabetic foot infections, septicemia, catheter-related blood-stream infections, bone and joint infections, febrile neutropenia, and respiratory infections, including COVID-19 pneumonia. The clinical cure on the eighth day was 95.7%, whereas the microbial success on the eighth day was 93.3% (n=60). For different types of infections, the clinical success rates ranged from 85.2% to 100%. There were only 30 treatment-emergent adverse events reported in 29 patients. Overall, about 95.6% of patients rated the efficacy as good to excellent, whereas only 3.8% of patients rated it satisfactory; for safety, 95.7% of patients rated it as good to excellent, with only 3.9% of patients rated it as satisfactory. Conclusions The excellent safety and efficacy profile of levonadifloxacin, when administered as an oral or intravenous therapy, makes it a desirable treatment modality for the management of various bacterial infections, including those caused by resistant pathogens such as MRSA and quinolone-resistant Staphylococcus aureus (QRSA). Features of levonadifloxacin, such as availability in both IV and oral form, minimal drug-drug interactions, lack of the need to adjust dosages in renal and hepatically impaired patients along with a broad spectrum of coverage, make it a suitable agent that meets several unmet clinical needs of physicians.

项与 Levonadifloxacin arginine salt 相关的新闻（医药）

2022-06-07

·PRNewswire

Antibiotic Resistance Market worth $18.34 Billion by 2030 - Exclusive Report by InsightAce Analytic

JERSEY CITY, N.J., June 7, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Antibiotic Resistance Market by Pathogen (DRSP, DRC, CD, MRSA, DRNG , DRNTS, Other Pathogen), Technology (Antibiotics, Phage, Pep/Lys, Antibodies, Vaccine, Others) Trends, Industry Competition Analysis, Revenue and Forecast To 2030." According to the latest research by InsightAce Analytic, the global Antibiotic Resistance market is valued at US$ 10.82 Billion in 2021, and it is expected to reach US$ 18.34 Billion by 2030, with a CAGR of 6.1% during the forecast period of 2022-2030. Antibiotic resistance is caused by antibiotic overuse and misuse (ABR). Most antibiotics are accessible over-the-counter, and many people use them without a doctor's prescription. The presence of international organizations in developed markets acts as a stimulant such as BARDA gives biotech companies financial assistance to complete early-stage research on innovative antibiotic-resistant illness remedies. This is projected to open up new revenue possibilities for participants in the worldwide Antibiotic Resistance market. Major companies' high expenditures and recent breakthroughs in creating numerous technologies have provided profitable revenue prospects for market expansion over the projection period. Request for Sample Pages: The global antibiotics industry is expanding because of rising antibiotics in poor and middle-income countries, pharmaceutical companies' significant investments in R&D, and an increase in the prevalence of infectious diseases. Major players' substantial investments and new advancements in the production of various end-use goods have provided lucrative revenue potential in developed markets. Furthermore, advances in nutrition, medicines, and immunization are expected to boost the antibiotic resistance industry forward during the forecast period. The discovery of advanced prospect molecules and the introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to propel market growth. However, The shortage of educated employees and strict safety rules may pose additional challenges to the antibiotic resistance market's growth over the upcoming years. Furthermore, a lack of investor interest in the research and development of antibiotic resistance medicines may impede the demand for antibiotic resistance throughout the projection period. The North America Antibiotic Resistance market will likely earn a significant revenue share and develop at a rapid CAGR shortly. Several new medicine launches and considerable treatment costs support the regional market's expansion. Also, the development of healthcare facilities in the region is expected to fuel the growth of the antibiotic resistance market in the upcoming years. The emergence of antibiotic-resistant illnesses and an increase in healthcare-acquired infections are expanding the patient pool in the United States. Enquire Before Buying: Furthermore, the presence of significant market players and increased collaboration among important companies for market penetration in the area gives opportunities for the worldwide Antibiotic Resistance market to develop. Greater engagement in terms of investment to combat resistance and implementing proper usage and stewardship standards for the use of antibiotics will boost market expansion over the upcoming years. Major market players operating in the Antibiotic Resistance market include The Medicines Company, Melinta Therapeutics, Arsanis, Phage Technologies S.A, Westway Health, Tetraphase Pharmaceuticals, BioVersys GmbH, Nabriva Therapeutics, Macrolide Pharmaceuticals, Nemesis Bioscience, C3J Therapeutics, Inc, EpiBiome, discuva, SmartPhage, AmpliPhi Biosciences, Pherecydes Pharma, Micreos, Procarta Biosystems, Lumavita, Madam Therapeutics, Priaxon, Biolytx Pharmaceuticals, AntibioTx, Xellia Pharmaceuticals, Paratek Pharmaceuticals, Synereca Pharmaceuticals, Allecra Therapeutics, Fixed Phage, Enanta Pharmaceuticals, Inc, Demuris, Prommune, Biosergen, Innovation Pharmaceuticals, Aviragen Therapeutics, Achillion Pharmaceuticals, ImmunNovative Developments, S.L., Achaogen, Inc., SelectX Pharmaceuticals, Inc., TaiGen Biotechnology Co., Ltd, Theravance Biopharma, Abbvie, KYORIN Pharmaceutical Co., Ltd., Iterum Therapeutics Limited, Forge Therapeutics, Alopexx Vaccine LLC, Integrated Biotherapeutics, Hennepin Life Sciences, Fedora Pharmaceuticals Inc, Contrafect Corporation, Basilea Pharmaceutica Ltd., AiCuris, RedHill Biopharma, Redx Pharma Plc/ Redx Anti Infectives Ltd., ABAC Therapeutics, Alaxia SAS, Antabio S.A.S, Auspherix Ltd, BioFilm Pharma, Centauri Therapeutics Ltd, Combioxin SA, Da Volterra, Debiopharm International SA, Deinobiotics/Deinove, Destiny Pharma plc, Eligo Bioscience, Helperby Therapeutics Ltd, Karveel Pharmaceuticals, MaaT Pharma, Motif BioSciences, Inc / Motif Bio PLC, Mutabilis SAS, Neem Biotech Ltd, Northern Antibiotics Oy (Ltd), Nosopharm, NovaBiotics Ltd, Phico Therapeutics Ltd, Polyphor Ltd, QureTech Bio AB, SetLance Srl, Ultupharma AB, Vaxdyn, Vibiosphen, Bioaster, Vivexia, KBP Biosciences, Absynth Biologics, Spero Therapeutics, Merck, Symphogen, Warp Drive Bio, Johnson & Johnson (Janssen), Pfizer, Allergan, Novartis, AstraZeneca, Cipla, DSM Sinochem Pharmaceuticals, Wockhardt Ltd., VenatoRx Pharmaceuticals, MicuRx, Entasis Therapeutics, Merlion Pharmaceuticals, Aridis Pharmaceuticals Inc, Other Prominent Players. Key Developments in the market: In April 2022, Johnson & Johnson announced the opening of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the University of Cape Town's Holistic Drug Discovery and Development (H3D) Centre. The H3D Satellite Center will aim to develop novel approaches to combat the current and growing danger of antimicrobial resistance (AMR), focusing on multidrug-resistant Gram-negative bacteria (MDR-GNB). In Sept 2021, Iterum Therapeutics plc announced that in the third quarter of 2021, the company held a Type A meeting with the US Food and Drug Administration (FDA) to discuss the steps required for resubmitting the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of simple urinary tract infections (uUTI). The FDA published a Complete Response Letter (CRL) to the company in July, asking for further evidence to support the approval of oral sulopenem for the treatment of adult women with uUTI. In Jan 2020, Wockhardt became the first Indian pharmaceutical company to receive approval from the drug regulator for two new antibiotics, which it aims to offer on the home market in the coming months. Emrok (injectable) and Emrok O (oral) has been authorised by the Drug Controller General of India (DCGI) for the treatment of severe bacterial skin and skin structure infections, including diabetic foot infections. In Nov 2019, Novartis announced the signing of a merger agreement and strategy with The Medicines Company. The anticipated purchase of The Medicines Company would enable Novartis to continue growing pipeline depth in a critical therapeutic area - a core pillar of its M&A strategy – and is in keeping with Novartis' strategic aim of delivering genuinely revolutionary medicines to patients. It would include a possible first-in-class siRNA inhibitor targeting PCSK9, which has the potential to revolutionise the treatment of high-risk patients with increased LDL-C. Market Segments Global Antibiotic Resistance Market, by Pathogen, 2020-2030 (Value US$ Bn) DRSP DRC CD MRSA DRNG DRNTS Other Pathogen Global Antibiotic Resistance Market, by Technology, 2020-2030 (Value US$ Bn) Antibiotics Phage Pep/Lys Antibodies Vaccine Others Global Antibiotic Resistance Market, by Region, 2020-2030 (Value US$ Bn) North America Europe Asia Pacific Latin America Middle East & Africa North America Antibiotic Resistance Market, by Country, 2020-2030 (Value US$ Bn) U.S. Canada Europe Antibiotic Resistance Market, by Country, 2020-2030 (Value US$ Bn) Germany France Italy Spain Russia Rest of Europe Asia Pacific Antibiotic Resistance Market, by Country, 2020-2030 (Value US$ Bn) India China Japan South Korea Australia & New Zealand Latin America Antibiotic Resistance Market, by Country, 2020-2030 (Value US$ Bn) Brazil Mexico Rest of Latin America Middle East & Africa Antibiotic Resistance Market, by Country, 2020-2030 (Value US$ Bn) GCC Countries South Africa Rest of Middle East & Africa Why should buy this report: To receive a comprehensive analysis of the prospects for the global Antibiotic Resistance market To receive an industry overview and future trends of the Antibiotic Resistance market To analyze the Antibiotic Resistance market drivers and challenges To get information on the Antibiotic Resistance market size (Value US$ Bn) forecast to 2030 Major investments, mergers & acquisitions in the Antibiotic Resistance market industry For customization @ Other Related Reports Published by InsightAce Analytic: Global Phage Therapy Market Global Therapeutic Proteins and Oral Vaccines Market Global Biosimilar Monoclonal Antibodies Market Global COVID-19 Therapeutics Market About Us: InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner. Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 718 593 4405 Email: [email protected] Site Visit: Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ SOURCE InsightAce Analytic Pvt. Ltd.

抗体生物类似药First in Class疫苗并购

2021-01-14

·GlobeNewswire

Antibiotics Market to Reach USD 39.06 Billion by 2027 at 2.1% CAGR; Surging Cases of Bacterial Infections to Incite Development, states Fortune Business Insights™

Pune, India, Jan. 14, 2021 (GLOBE NEWSWIRE) -- The global antibiotics market size is expected to reach USD 39.06 billion in 2027 at a CAGR of 2.1% during the forecast period. The increasing R&D for the development of antimicrobials in multidrug-resistant bacteria is expected to have a tremendous impact on the global market, states Fortune Business Insights, in a report. The market size stood at USD 43.30 billion in 2019. Increasing Cases of Bacterial Infections to Boost Market The increasing cases of bacterial infections will spur demand for antimicrobials, which, in turn, will augur well for the market. The rising incidence of tuberculosis, malaria, pneumonia, bacterial skin infections, urinary tract infections (UTI), and others will bolster the market's healthy growth during the forecast period. As per the estimates of WHO, the worldwide prevalence of tuberculosis was 10 million in 2019. According to the Centers for Disease Control and Prevention, 1.7 million HAIs occur every year in the U.S., 32% of which are hospital-acquired UTIs. The increasing government efforts to prevent hospital-acquired infections (HAI), catheter, and ventilator-associated infections will create lucrative opportunities for the market in the forthcoming years. Request a Sample Copy of the Research Report: Adoption of Digital Health Technologies to Promote Growth Amid Coronavirus The declined patient volume in standalone clinics and hospitals has forced doctors to adopt digital health technologies to sustain their business. Pharmaceuticals and medical devices companies have incurred huge losses due to the economic crisis caused by the pandemic. Moreover, dopped sales observed by key manufacturers can simultaneously dampen the growth of the market. For instance, nine months of Pfizer’s Zithromax sales decreased by 14.2% in 2020 compared to 2019. Similarly, Cubicin, manufactured by Merck & Co., Inc., witnessed a decline of 44.0% in sale during nine months of 2020 as compared to the previous year Substantial R&D Investments by Major Companies to Consolidate Business Prominent companies such as Merck & Co., Inc, Sandoz, Taisho Pharmaceutical Holdings, Daiichi Sankyo Company, Limited are investing in R&D to strengthen their position in the industry. Moreover, the increasing approvals for innovative therapies by the FDA can spur lucrative opportunities for the market. For instance, in August 2019, TB Alliance, a non-profit organization, received FDA approval for Pretomanid, as part of combination therapy with linezolid and bedaquiline to treat TB. Click here to get the short-term and long-term impact of COVID-19 on this Market. Please visit: Heavy Demand for Antibiotics to Contribute Growth in Asia Pacific The market in Asia Pacific is expected to hold the largest share during the forecast period due to the high consumption of antibiotics. According to an article published in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS), China, India, and Pakistan witnessed a rise of 103%, 79%, and 69%, respectively, in antibiotic consumption during 2000-2015. The growing prevalence of bacterial infections coupled with the high use of antibiotics will spur lucrative opportunities for the Asia Pacific market. Quick Buy - Antibiotics Market Research Report: Key Development: January 2020: Wockhardt announced that it had received approval from The Drug Controller General of India (DCGI) for Emrok (injectable) and Emrok O (oral) in acute bacterial skin and skin structure infections, including diabetic foot infections. The Report Lists the Key Players in the Antibiotics Market: Pfizer Inc. (New York, U.S.) GlaxoSmithKline plc (Brentford, U.K.) Merck & Co., Inc. (New Jersey, U.S.) Sandoz (Novartis AG) (Holzkirchen, Germany) Daiichi Sankyo Company, Limited (Tokyo, Japan) Taisho Pharmaceutical Holdings (Tokyo, Japan) Melinta Therapeutics (New Jersey, U.S.) Other Prominent Players Have Any Query? Ask Our Experts: Table of Contents: Introduction Research Scope Market Segmentation Research Methodology Definitions and Assumptions Executive Summary Market Dynamics Market Drivers Market Restraints Market Opportunities Key Insights Prevalence of Key Bacterial Infections– For Key Countries/ Regions Antimicrobial Resistance Statistics – For Key Countries/ Regions Pipeline Snapshot New Product Launches Key Industry Developments – Partnerships, Mergers, & Acquisitions Impact of COVID-19 Pandemic on Antibiotics Market Global Antibiotics Market Analysis, Insights and Forecast, 2016-2027 Key Findings / Summary Market Analysis, Insights and Forecast – By Drug Class Cephalosporin Penicillins Fluoroquinolones Macrolides Others Market Analysis, Insights and Forecast – By Route of Administration Oral Parenteral Market Analysis, Insights and Forecast – By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Market Analysis, Insights and Forecast – By Region North America Europe Asia Pacific Latin America Middle East & Africa TOC Continued….! Get your Customized Research Report: SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION: Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc. Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility Number of procedures and average price of procedures Replacement rate and pricing of capital equipment Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities Market & technological trends, new product developments, product pipeline. Have a Look at Related Reports: Bone Void Fillers Market Share & Industry Analysis, By Type (Demineralized Bone Matrix (DBM), Collagen Matrix, Calcium Sulfate, Tri-calcium Phosphate, and Others), By Form (Gel, Granules, Paste, Putty, and Others), By End User (Hospitals, Specialty Clinics and Others), and Regional Forecast, 2020-2027 Intensive Care Unit (ICU) Equipment Market Share and Covid-19 Impact Analysis, By Product (Beds, Ventilators, Pulse Oximeters, Dialysis Equipment, and Others), By Patient (Adult and Pediatric), By Application (Neurology, Cardiology, Respiratory, Renal, Oncology, Trauma, and Others), By End-User (Hospitals, Specialty Clinics, and Others) and Regional Forecast, 2020-2027 Bone Graft Substitutes Market Share & Industry Analysis, By Type (Autograft, Allograft, Demineralized bone matrix (DBM), Synthetic, Xenograft), By Application (Spinal Fusion, Joint Reconstruction, Foot & Ankle, Others), By End User (Hospitals, Specialty Clinics) and Regional Forecast, 2020-2027 Telerehabilitation Market Share and Covid-19 Impact Analysis, By Type (Products, Services), By Application (Occupational Therapy, Physical Therapy, Chronic Diseases, and Others), By End-User (Healthcare Facilities and Homecare); and Regional Forecast, 2020-2027 Ventilator Market Share & Covid-19 Impact Analysis, By Type (Adult, and Paediatric & Neonatal), By Interface (Invasive, and Non-invasive), By End User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2020-2027 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India. Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights™ LinkedIn | Twitter | Blogs

并购

100 项与 Levonadifloxacin arginine salt 相关的药物交易

登录后查看更多信息